In this whitepaper, we outline a continental market-shaping strategy for a sustainable vaccine manufacturing footprint in Africa to improve health outcomes and save lives.
The inequitable rollout of COVID-19 vaccines drew global attention to the lack of vaccine manufacturing capacity in Africa. Significant political and financial investment have since been made on the continent, creating growth momentum behind the industry. This white paper offers a view on targeting a compromise between the three major objectives global health stakeholders have towards African vaccine manufacturing expansion and complements our recent briefing, coauthored with Africa CDC and PATH, where we examine current and planned vaccine manufacturing capacity in Africa.
